人工智能医疗科技领域的先驱，Carlsmed公司近日宣布，成功完成了由B Capital和US Venture Partners联合领投的5250万美元C轮融资。这笔资金的注入将极大地推动该公司在人工智能个性化手术领域的创新步伐。
Carlsmed的核心技术aprevo ®个性化脊柱手术平台，专为腰椎融合手术设计，将在新一轮融资的支持下，加快商业化进程。此外，公司还计划利用这笔资金开发针对颈椎融合手术的aprevo ®平台，预计该平台将于2025年正式推出。这一创新举措将进一步拓宽Carlsmed在精准医疗领域的应用范围，为患者提供更加精准、个性化的治疗方案。
此次融资彰显了投资者对Carlsmed在医疗科技尤其是人工智能手术应用方面的信心。通过aprevo ®平台，Carlsmed有望引领脊柱手术进入一个全新的个性化时代，提高手术成功率，减少并发症，同时降低医疗成本。
B Capital和US Venture Partners的领导投资，不仅为Carlsmed带来了资金支持，也为其在全球医疗市场的拓展提供了战略指导和行业资源。Carlsmed表示，将利用这些资源加速产品研发，深化与医疗专业人员的合作，以期在全球范围内推广其创新的手术解决方案。
未来，Carlsmed将继续致力于将人工智能技术与医疗实践相结合，以期在改善患者预后、提高手术效率方面做出更大的贡献。
英语如下：
**News Title:** “Carlsmed Raises $52.5 Million in Series C Funding to Accelerate AI-Powered Personalized Spine Surgery Platform”
**Keywords:** Carlsmed, Artificial Intelligence, Surgery Platform
**News Content:**
Title: Carlsmed Secures $52.5 Million in Series C Funding to Speed Up Commercialization of Personalized Surgery Platform aprevo ®
Carlsmed, a pioneer in artificial intelligence (AI) medical technology, has announced the completion of a $52.5 million Series C funding round led by B Capital and US Venture Partners. The investment will significantly propel the company’s innovation in AI-driven personalized surgery.
At the heart of Carlsmed’s offerings is the aprevo ® personalized spine surgery platform, tailored for lumbar fusion surgeries, which will benefit from the new funding to accelerate its commercialization. The company also intends to utilize the capital to develop an aprevo ® platform for cervical fusion surgeries, expected to launch in 2025. This expansion will broaden Carlsmed’s reach in precision medicine, enabling more precise and individualized treatment options for patients.
This financing round underscores investors’ confidence in Carlsmed’s capabilities in medical technology, particularly in AI-assisted surgical applications. With the aprevo ® platform, Carlsmed aims to usher in a new era of personalized spine surgery, enhancing success rates, reducing complications, and lowering healthcare costs.
The lead investment from B Capital and US Venture Partners not only provides financial backing but also offers strategic guidance and industry resources for Carlsmed’s global market expansion. The company plans to leverage these resources to accelerate product development and deepen collaborations with medical professionals, aiming to promote its innovative surgical solutions worldwide.
Moving forward, Carlsmed remains committed to integrating AI technology with medical practice to make substantial contributions to improving patient outcomes and enhancing surgical efficiency.
【来源】https://www.businesswire.com/news/home/20240318820510/en/Carlsmed-Raises-52.5M-in-Series-C-Financing-to-Advance-Personalized-Spine-Surgery
Views: 1